Principal Financial Group
KROS icon

Principal Financial Group’s Keros Therapeutics KROS Stock Holding History

Principal Financial Group’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$683K Buy
63,807
+4,213
+7% +$46.9K ﹤0.01% 1982
2026
Q1 		$658K Buy
+59,594
New +$920K ﹤0.01% 2002
2024
Q3 		– Sell
-5,265
Closed -$241K – 2321
2024
Q2 		$241K Sell
5,265
-1,798
-25% -$96.6K ﹤0.01% 2105
2024
Q1 		$468K Buy
7,063
+574
+9% +$34K ﹤0.01% 1997
2023
Q4 		$258K Sell
6,489
-23
-0.4% -$721 ﹤0.01% 2102
2023
Q3 		$208K Sell
6,512
-100
-2% -$3.73K ﹤0.01% 2158
2023
Q2 		$266K Buy
6,612
+735
+13% +$32.2K ﹤0.01% 2106
2023
Q1 		$251K Sell
5,877
-400
-6% -$20.2K ﹤0.01% 2128
2022
Q4 		$301K Buy
+6,277
New +$293K ﹤0.01% 2095
2021
Q1 		– Sell
-3,140
Closed -$221K – 2490
2020
Q4 		$221K Buy
+3,140
New +$198K ﹤0.01% 2293

Other funds holding KROS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Principal Financial Group's KROS Position: Q2 2026 in Review

Principal Financial Group increased its Keros Therapeutics (KROS) stake by 7.1% in Q2 2026, buying an estimated $46.9K and bringing the position to 63,807 shares worth $683K. The position accounts for ﹤0.01% of the portfolio, ranked #1982.

Principal Financial Group first reported a position in KROS in Q4 2020 and has held it in 10 quarters since. 132 funds tracked by Wall St. Rank hold KROS as of Q2 2026.

  • Principal Financial Group held 63,807 shares of Keros Therapeutics worth $683K as of Q2 2026.
  • Principal Financial Group bought 4,213 Keros Therapeutics shares in Q2 2026, an estimated $46.9K.
  • Keros Therapeutics made up ﹤0.01% of Principal Financial Group's portfolio in Q2 2026, its #1982 holding.
  • Principal Financial Group first reported a position in Keros Therapeutics in Q4 2020 and has held it in 10 quarters since.
  • 132 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2026.

Based on Principal Financial Group's 13F filing for Q2 2026, filed 4 Aug 2026.